Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05972694 · ClinicalTrials.gov registry record · NA

Effect of Grapes in Inflammatory Bowel Disease

A NA study of Crohn Disease, sponsored by Case Western Reserve University.

Completed
Registry status
NA
Development phase
21
Enrollment target
1
Study location

NCT05972694 is a NA study of Crohn Disease that has completed, run by Case Western Reserve University. The registered enrollment target is 21 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05972694, a NA study of Crohn Disease, has completed, sponsored by Case Western Reserve University.

COMPLETED
Registry status
NA
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

The overall objective of this pilot intervention study is to determine the impact of grape powder (46g/day freeze dried whole grape powder provided by the California Table Grape Commission) on the gut microbiotacomposition in adult patients with the IBD subtype Crohn's disease (CD).

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Freeze dried grape powder

Study Locations (1)

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2024-09-16
Est. Completion 2026-02-15
Phase NA

Sponsor

Case Western Reserve University

141 total trials

What the Registry Record Tells You About NCT05972694

The ClinicalTrials.gov registry entry for NCT05972694 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (90% lower). The listed sponsor is Case Western Reserve University, which has 141 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 1 intervention - of which Freeze dried grape powder is the first listed.

NCT05972694 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT05972694 about?

NCT05972694 is a clinical study titled "Effect of Grapes in Inflammatory Bowel Disease". The overall objective of this pilot intervention study is to determine the impact of grape powder (46g/day freeze dried whole grape powder provided by the California Table Grape Commission) on the gut microbiotacomposition in adult patients with the IBD subtype Crohn's disease (CD).

What is the current status of trial NCT05972694?

This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2024-09-16. Estimated completion is 2026-02-15.

What conditions does trial NCT05972694 study?

This clinical trial studies the following conditions: Crohn Disease.

What interventions are being tested in trial NCT05972694?

The interventions under investigation include: Freeze dried grape powder (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05972694?

This trial is sponsored by Case Western Reserve University, which has 141 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05972694 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Crohn Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.